Evaluation of safety and pharmacodinamy of TERAP C: Aa vaccine preparation for therapeutic use in the treatment of chronic hepatitis caused by hepatitis C virus. Phase I Clinical Trial, not controlled, not randomized, not blinded
Latest Information Update: 14 Oct 2020
At a glance
- Drugs CIGB 230 (Primary)
- Indications Hepatitis C
- Focus Adverse reactions
Most Recent Events
- 31 Jul 2013 Status changed from active, no longer recruiting to completed as reported by Cuban Clinical Trial Registry.
- 13 Feb 2013 Status changed from completed to active, no longer recruiting as reported by Cuban Clinical Trial Registry.
- 13 Sep 2011 New trial record